Physicians are conducting a clinical trial for patients with sarcoma. Sarcoma is a type of bone cancer that can be treated with chemotherapy which can affect the bone marrow, where blood cells are produced. Neutrophils are a type of white blood cells that fight infection and are produced in the bone marrow. If the neutrophil count becomes too low due to chemotherapy, a potentially serious condition called neutropenia occurs. Neutropenia is serious because it can affect the body's ability to protect against many types of infections. Pegfilgrastim is an investigational drug being evaluated for its potential ability to increase the number of neutrophils. The purpose of this study is to determine the safety and effectiveness of pegfilgrastim in preventing neutropenia following chemotherapy in patients up through the age of 11 with sarcoma.

Condition	Treatment or Intervention	Phase
Sarcoma Neutropenia	Drug: pegfilgrastim	Phase II

Ages Eligible for Study:  up to  11 Years,  Genders Eligible for Study:  Both

Criteria

• Sarcoma
• No previous chemotherapy or radiotherapy
• Patients who will be receiving chemotherapy consisting of Vincristine, Doxorubicin, Cyclophosphamide, Etoposide, Ifosfamide, and Mesna

For additional information regarding investigative sites for this trial, contact the Amgen Call Center at      1-866-57AMGEN (1-866-572-6436) 

Arkansas
      Research Center, Little Rock,  Arkansas,  United States; Recruiting
California
      Research Center, Orange,  California,  United States; Recruiting
Tennessee
      Research Center, Memphis,  Tennessee,  United States; Recruiting

Study ID Numbers:  990130
Record last reviewed:  April 2004
Record first received:  May 3, 2002
ClinicalTrials.gov Identifier:  NCT00035620
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-11-10